Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review
The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We conducted a systematic review of studies evaluating the cost-effectiveness (CE) of interventions to prevent type 2 diabetes (T2D) among high-risk individuals and whole populations. RESEARCH DESIGN AND METHODS: Interventions targeting high-risk individuals are those that identify people at high risk of developing T2D and then treat them with either lifestyle or metformin interventions. Population-based prevention strategies are those that focus on the whole population regardless of the level of risk, creating public health impact through policy implementation, campaigns, and other environmental strategies. We systematically searched seven electronic databases for studies published in English between 2008 and 2017. We grouped lifestyle interventions targeting high-risk individuals by delivery method and personnel type. We used the median incremental cost-effectiveness ratio (ICER), measured in cost per quality-adjusted life year (QALY) or cost saved to measure the CE of interventions. We used the $50,000/QALY threshold to determine whether an intervention was cost-effective or not. ICERs are reported in 2017 U.S. dollars. RESULTS: Our review included 39 studies: 28 on interventions targeting high-risk individuals and 11 targeting whole populations. Both lifestyle and metformin interventions in high-risk individuals were cost-effective from a health care system or a societal perspective, with median ICERs of $12,510/QALY and $17,089/QALY, respectively, compared with no intervention. Among lifestyle interventions, those that followed a Diabetes Prevention Program (DPP) curriculum had a median ICER of $6,212/QALY, while those that did not follow a DPP curriculum had a median ICER of $13,228/QALY. Compared with lifestyle interventions delivered one-on-one or by a health professional, those offered in a group setting or provided by a combination of health professionals and lay health workers had lower ICERs. Among population-based interventions, taxing sugar-sweetened beverages was cost-saving from both the health care system and governmental perspectives. Evaluations of other population-based interventions—including fruit and vegetable subsidies, community-based education programs, and modifications to the built environment—showed inconsistent results. CONCLUSIONS: Most of the T2D prevention interventions included in our review were found to be either cost-effective or cost-saving. Our findings may help decision makers set priorities and allocate resources for T2D prevention in real-world settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30097-9 · Cited by 816
Ali, M. K., Echouffo-Tcheugui, J. B., & Williamson, D. F. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1009 · Cited by 594
Braithwaite, R. S., Meltzer, D. O., King, J. T., Leslie, D., & Roberts, M. S. (2008) · Medical Care · doi:10.1097/mlr.0b013e31815c31a7 · Cited by 579
Dunkley, A. J., Bodicoat, D. H., Greaves, C. J., Russell, C., Yates, T., Davies, M. J., & Khunti, K. (2014) · Diabetes Care · doi:10.2337/dc13-2195 · Cited by 542
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491 · cited 3×
“Quality Assessment of the Included Studies To assess the quality of included studies, weuseda tool basedonTheBMJauthors’ guide for economic studies (22), which was used previously (20).”
BackgroundMethodInfluentialSelf-citationImpact of the Berkeley Excise Tax on Sugar-Sweetened Beverage Consumption
Falbe, J., Thompson, H. R., Becker, C. M., Rojas, N., McCulloch, C. E., & Madsen, K. A. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303362 · Cited by 464 · cited 1×
“(Berkeley, for example) have led decision makers to explore the feasibility and effectiveness of scaling up such policies (7,8).”
BackgroundThe 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Research works printed but not linked: 3
- International Diabetes Federation, 2019, IDF Diabetes Atlas
- Centers for Disease Control Prevention, 2020, National Diabetes Statistic Report, 2020
- International Diabetes Federation, 2016, Cost-Effective Solutions for the Prevention of Type 2 Diabetes
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
“screening has been reinforced in cohort studies (81,82).”
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Introduction: Standards of Medical Care in Diabetes—2022
American Diabetes Association (2022) · Diabetes Care · doi:10.2337/dc22-sint · Cited by 807
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Healthy Eating and Active Lifestyles: Best Practices in Public Health
OECD (2022) · OECD eBooks · doi:10.1787/40f65568-en · Cited by 276
Gregg, E. W., Buckley, J., Ali, M. K., Davies, J., Flood, D., Mehta, R., Griffiths, B., Lim, L.-L., Manne-Goehler, J., Pearson-Stuttard, J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00001-6 · Cited by 232
Introduction: Standards of Medical Care in Diabetes—2021
(2021) · Diabetes Care · doi:10.2337/dc21-sint · Cited by 265
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s003 · Cited by 204
3. Prevention or Delay of Type 2 Diabetes:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s003 · Cited by 200
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s003 · Cited by 144
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s003 · Cited by 132
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 206
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s003 · Cited by 144
Clinical utility of polygenic risk scores for coronary artery disease
Klarin, D., & Natarajan, P. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00638-w · Cited by 152
Sandforth, A., von Schwartzenberg, R. J., Arreola, E. V., Hanson, R. L., Sancar, G., Katzenstein, S., Lange, K., Preißl, H., Dreher, S. I., Weigert, C., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00235-8 · Cited by 100
Eichelmann, F., Prada, M., Sellem, L., Jackson, K. G., Salas‐Salvadó, J., Razquín, C., Estruch, R., Friedén, M., Rosqvist, F., Risérus, U., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03124-1 · Cited by 100
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 106
Namazi, N., Moghaddam, S. S., Esmaeili, S., Peimani, M., Tehrani, Y. S., Bandarian, F., Shobeiri, P., Nasli‐Esfahani, E., Malekpour, M., Rezaei, N., et al. (2024) · BMC Public Health · doi:10.1186/s12889-023-16540-8 · Cited by 63
Golovaty, I., Ritchie, N. D., Tuomilehto, J. O., Mohan, V., Ali, M. K., Gregg, E. W., Bergman, M., & Moin, T. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110195 · Cited by 59
Socioeconomic inequalities in lifestyle risk factors across low- and middle-income countries
Dieteren, C., & Bonfrer, I. (2021) · BMC Public Health · doi:10.1186/s12889-021-11014-1 · Cited by 53
Pharmacist-Managed Diabetes Programs: Improving Treatment Adherence and Patient Outcomes
Orabone, A. W., Do, V., & Cohen, E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s342936 · Cited by 53
“Fortunately, for patients who live with diabetes, appropriate management has demonstrated to be cost-effective and improve outcomes.(3)”
BackgroundFeasibility of prevention of type 2 diabetes in low- and middle-income countries
Kengne, A. P., & Ramachandran, A. (2024) · Diabetologia · doi:10.1007/s00125-023-06085-1 · Cited by 51
“However, evaluation of other strategies including fruit and vegetable subsidies, educational programmes (targeting improvements in physical activity and diet) and modifications to the built environment showed inconsistent results [66].”
BackgroundLifestyle interventions for cardiometabolic health
Rutters, F., den Braver, N. R., Lakerveld, J., Mackenbach, J. D., van der Ploeg, H. P., Griffin, S. J., Elders, P. J. M., & Beulens, J. W. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03373-0 · Cited by 49
Type 2 Diabetes Prevention Programs—From Proof-of-Concept Trials to National Intervention and Beyond
Tuomilehto, J. O., Uusitupa, M. I. J., Gregg, E. W., & Lindström, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051876 · Cited by 46
“In general, including persons of lower risk will increase the overall number of cases prevented but reduce efficiency and cost-effectiveness by spending resources on persons with a relatively low risk of progression to diabetes [59].”
BackgroundSignificance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
Dwibedi, C. K., Axelsson, A. S., Abrahamsson, B., Fahey, J. W., Asplund, O., Hansson, O., Ahlqvist, E., Tremaroli, V., Bäckhed, F., & Rosengren, A. H. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01932-w · Cited by 41
“In view of the low cost of BSE, it is also of note that risk reductions as small as 5% have been shown to be clinically cost-effective owing to the large societal costs of diabetes 37 .”
Chakkalakal, R. J., Galaviz, K. I., Thirunavukkarasu, S., Shah, M. K., & Narayan, K. M. V. (2024) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-060222-023417 · Cited by 35
The prediabetes conundrum: striking the balance between risk and resources
Blond, M. B., Færch, K., Herder, C., Ziegler, D., & Stehouwer, C. D. A. (2023) · Diabetologia · doi:10.1007/s00125-023-05890-y · Cited by 40
Effective data-driven precision medicine by cluster-applied deep reinforcement learning
Oh, S. H., Lee, S. J., & Park, J. (2022) · Knowledge-Based Systems · doi:10.1016/j.knosys.2022.109877 · Cited by 38
Prakoso, D. A., Istiono, W., Mahendradhata, Y., & Arini, M. (2023) · BMC Public Health · doi:10.1186/s12889-023-16840-z · Cited by 35
Kazibwe, J., Gad, M. M., Abassah-Konadu, E., Amankwah, I., Owusu, R., Gulbi, G., Rueda, S. T., Asare, B. A., Vassall, A., & Ruiz, F. J. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001904 · Cited by 34
Park, J., Bigman, E. T., & Zhang, P. (2022) · Diabetes Care · doi:10.2337/dc22-0445 · Cited by 29
“Lifestyle interventions are effective in reducing T2D among those at high risk (23,24), and the National Diabetes Prevention Program (National DPP) implements lifestyle change programs nationwide (25).”
Self-citationData-Driven Allocation of Preventive Care with Application to Diabetes Mellitus Type II
Kraus, M., Feuerriegel, S., & Saar‐Tsechansky, M. (2023) · Manufacturing & Service Operations Management · doi:10.1287/msom.2021.0251 · Cited by 42
“…of preventive care by comparing different preventive treatments or by comparing a preventive treatment against a placebo group (e. g., Breeze et al. 2017, Cohen et al. 2008, Zhou et al. 2020); but in these cases, the allocation rule was ex ante given and thus not the focus of the study.”
BackgroundBeltran-Valls, M. R., Cabanas-Sánchez, V., Sadarangani, K. P., Rodríguez-Artalejo, F., Moliner-Urdiales, D., & Martínez-Gómez, D. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101410 · Cited by 21
Healthcare utilisation patterns and contributory factors among middle-aged adults: a scoping review
Ng, Y. H., Low, A. J. A., Chan, C., Lim, Y. L., Lee, C. E., Tan, H. K., & Ng, Q. X. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00715-z · Cited by 25
Use and Impact of Type 2 Diabetes Prevention Interventions
Campione, J. R., Ritchie, N. D., Fishbein, H. A., Mardon, R. E., Johnson, M. C., Pace, W. D., Birch, R. J., Seeholzer, E. L., Zhang, X., Proia, K. K., et al. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.04.002 · Cited by 20
Self-citationDahal, P. K., Rawal, L. B., Mahumud, R. A., Paudel, G., Sugishita, T., & Vandelanotte, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191710799 · Cited by 21
“A previous systematic review (studies included between 2008 and 2017) among individuals at high risk of T2DM reported that diabetes prevention programs (using health behavior interventions) are either cost-effective or cost-saving [61].”
BackgroundKuo, S., Ye, W., Wang, D., McEwen, L. N., Villatoro Santos, C., & Herman, W. H. (2025) · Diabetes Care · doi:10.2337/dc24-1110 · Cited by 19
“Lifestyle interventions provided in group settings or by a combination of health professionals and lay health workers had lower ICERs compared with those delivered one-on-one or by health professionals alone (10).”
InfluentialZhang, Y., Yang, X., & Wan, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1537303 · Cited by 20
Robinson, J., Nitschke, E., Tovar, A. P., Mattar, L., Gottesman, K., Hamlett, P., & Rozga, M. (2023) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2023.04.004 · Cited by 19
Lihme, F., Savu, A., Basit, S., Sia, W. W., Yeung, R. O., Barrett, O., Luoma, L. M., Ngwezi, D. P., Davidge, S. T., Norris, C. M., et al. (2023) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14703 · Cited by 19
“44,45 However, whether such interventions could be successfully and efficaciously implemented on a population-wide scale in women of reproductive age, remains unknown.”
BackgroundOlstad, D. L., Beall, R. F., Spackman, E., Dunn, S., Lipscombe, L. L., Williams, K., Oster, R. T., Scott, S., Zimmermann, G. L., McBrien, K., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-050006 · Cited by 21
Bosetti, R., Tabatabai, L. S., Naufal, G., Menser, T. L., & Kash, B. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260139 · Cited by 19
Kokkorakis, M., Folkertsma, P., van Dam, S., Sirotin, N., Taheri, S., Chagoury, O. L., Idaghdour, Y., Henning, R. H., Forte, J. C., Mantzoros, C. S., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102235 · Cited by 15
“32 Based on our reclassi fi cation analyses, all models developed herein correctly reclassify predicted T2D cases and, in many instances, outperform the currently available models.”
ResultSquires, H., Kelly, M. P., Gilbert, N., Sniehotta, F. F., & Purshouse, R. C. (2023) · Health Economics · doi:10.1002/hec.4754 · Cited by 16
Michaud, T. L., Wilson, K. E., Katula, J. A., You, W., & Estabrooks, P. A. (2023) · Translational Behavioral Medicine · doi:10.1093/tbm/ibad008 · Cited by 12
Mackenbach, J. D., Stuber, J. M., & Beulens, J. W. J. (2024) · Diabetologia · doi:10.1007/s00125-024-06330-1 · Cited by 12
“Most intensive lifestyle interventions can be considered very cost effective [2, 3].”
Taylor, R., Sullivan, D., Reeves, P., Kerr, N., Sawyer, A., Schwartzkoff, E., Bailey, A. W., Williams, C. M., & Hure, A. J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20126139 · Cited by 12
“Eleven systematic reviews [18,21,22,30,33,35,38,40,42,43,48] concluded that at least 70% of studies were highly rated for their methodological quality (Table 7).”
BackgroundInfluentialDia, N., Ferekh, S., Jabbour, S., Akiki, Z., Rahal, M. K., Khoury, M., & Akel, M. (2022) · Pharmacy Practice · doi:10.18549/pharmpract.2022.1.2608 · Cited by 11
Guariguata, L., García, L., Sobers, N., Ferguson, T. S., Woodcock, J., Samuels, T. A., Guell, C., & Unwin, N. C. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000436 · Cited by 13
“Downstream interventions in the health system for people at high risk or with diabetes are an important component that can greatly improve the quality of life and reduce disability in those affected [83, 84].”
BackgroundMcManus, E. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00487-6 · Cited by 10
“There have also been several literature reviews of decision-analytic models in the prevention of type 2 diabetes [43–47].”
BackgroundAn overview of environmental risk factors for type 2 diabetes research using network science tools
Cao, X., Yu, H., Yu, Q., Qin, J., Zhao, Y., Yang, X., & Gao, S. (2024) · Digital Health · doi:10.1177/20552076241271722 · Cited by 13
“6 Despite the undeniable impact of genetic predisposition, it remains a realm where our ability to inter-vene directly is constrained.”
BackgroundCáceres-Gutiérrez, D. A., Bonilla-Bonilla, D. M., Liscano, Y., & Díaz-Vallejo, J. A. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15110504 · Cited by 13
“Although tangible clinical benefits have been documented, such as HbA1c reductions of up to 1.9%, the absence of cost-effectiveness evaluations overlooks economic realities [30].”
InfluentialDineen, T. E., Bean, C. N., Cranston, K. D., MacPherson, M., & Jung, M. E. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.728612 · Cited by 10
Gregg, E. W., & Moin, T. (2021) · JAMA · doi:10.1001/jama.2021.12559 · Cited by 9
Chen, S.-Y., Li, X.-X., Lu, F., & Shen, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1665074 · Cited by 10
Shao, Y., Wang, Y., Bigman, E. T., Imperatore, G., Holliday, C. S., & Zhang, P. (2024) · Diabetes Care · doi:10.2337/dc24-0466 · Cited by 8
Self-citationLloyd, M., Temple, V. A., Foley, J. T., Yeatman, S., Lunsky, Y., Huang, A., & Balogh, R. S. (2024) · Diabetic Medicine · doi:10.1111/dme.15393 · Cited by 9
“3 However, diabetes prevention strategies used for the general population may not translate well for people with IDD.”
Diabetes prevention after gestational diabetes: challenges and opportunities
Dunne, P., Sherry, D., & O'Reilly, S. L. (2024) · Proceedings of The Nutrition Society · doi:10.1017/s0029665124007456 · Cited by 9
“Effective interventions targeting the prevention of T2D can simultaneously reduce health burdens and healthcare costs, so investment in future prevention programmes has the potential to considerably alleviate future strain on already limited health resources (95) .”
Zhang, Y.-C., Xiong, F., Zhao, R., Shi, T., Lü, J., & Yang, J. (2021) · International Journal of Endocrinology · doi:10.1155/2021/4350418 · Cited by 8
“Fortunately, T2DM can be prevented or delayed by targeting individuals at high risk [3].”
BackgroundGad, M. M., Kazibwe, J., Abassah-Konadu, E., Amankwah, I., Owusu, R., Gulbi, G., Torres-Rueda, S., Asare, B., Vassall, A., & Ruiz, F. J. (2023) · medRxiv · doi:10.1101/2023.04.19.23288806 · Cited by 8
Dineen, T. E., Bean, C. N., Bohlouli, A., Percival, S. L., Vis‐Dunbar, M., & Jung, M. E. (2025) · Implementation Science Communications · doi:10.1186/s43058-025-00757-2 · Cited by 7
“Diabetes prevention programs (DPP), of which the majority target diet and exercise modifications, have been translated into clinical practice and community settings demonstrating effectiveness and cost-effectiveness [6, 7].”
Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes
Sutkowska, E., Fecka, I., Marciniak, D. M., Bednarska, K., Sutkowska, M., & Hap, K. (2023) · Biomedicines · doi:10.3390/biomedicines11112968 · Cited by 8
“Prediabetes (pre‑DM) can lead to diabetes mellitus (DM) [1] and because, in most cases, there is a conglomeration of numerous cardiovascular risk factors (the so‑called metabolic syndrome) [2], it remains in the attention of the medical community in the con‑ text of treatment and prevention [3–5].”
BackgroundSquires, H., Kelly, M. P., Gilbert, N., Sniehotta, F. F., Purshouse, R. C., García, L., Breeze, P. R., Brennan, A., Gardner, B., Bright, S., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20225-1 · Cited by 8
Bower, P., Soiland‐Reyes, C., Bennett, C., Brunton, L., Burch, P., Cameron, E., Chandola, T., Chatzi, G., Cotterill, S., French, D., et al. (2025) · Health and Social Care Delivery Research · doi:10.3310/mwkj5102 · Cited by 8
“28 The review identified 28 studies using a high-risk intervention approach (i.e. those identifying people at high risk of developing T2D Another factor that drives whether an intervention is considered cost-effective is the evaluation perspective (i.e. whether healthcare, social care and societal…”
Baatiema, L., Strachan, D. L., Okoibhole, L. O., Kretchy, I. A., Kushitor, M. K., Awuah, R. B., Sanuade, O. A., Danyki, E. K., Amon, S., Adjaye-Gbewonyo, K., et al. (2024) · Global Health Action · doi:10.1080/16549716.2024.2364498 · Cited by 8
“Addressing these gaps is required to implement the best policy and practices for the prevention and management of diabetes advocated by the WHO [25–28].”
BackgroundHow to Fix a Broken Health Care System: Pathways to Maximize Health and Well-being for All
Chin, M. H., Bruch, J. D., Grogan, C. M., Huang, E. S., Kandula, N. R., Kim, D. D., Peek, M. E., & Pollack, H. A. (2025) · Diabetes Care · doi:10.2337/dci25-0001 · Cited by 7
Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence?
van Dover, T. J., & Kim, D. D. (2021) · Value in Health · doi:10.1016/j.jval.2021.03.017 · Cited by 8
Interventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Drake, C., Granados, I., Rader, A., Brucker, A., Hoeffler, S., Goldstein, B. A., Chamorro, C., Johnson, F., Hinz, E. M., Bedoya, A., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107655 · Cited by 7
Martin-Ridaura, C., Ochoa-Esteban, D., Berlinches-Zapero, C., Ruiz-Fernández, D., Sanz-Martín, V., Gavira-Izquierdo, R., March, S., López‐Toribio, M., Arcones, M. C., The ALAS Project Working Group, et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21531-7 · Cited by 7
“Age < 44 years 228 (15) 56 (12) 172 (16)”
Wang, Y., Zhang, P., Xing, Y., Shi, H., Cui, Y.-P., Wei, Y., Zhang, K., Wu, X., Ji, H. Q., Xu, X., et al. (2024) · Journal of Medical Internet Research · doi:10.2196/57814 · Cited by 7
“Consequently, it curtails the financial burden associated with untimely interventions [16,17].”
Self-citationBrown, S. A., Becker, H., García, A. A., Velasquez, M. M., Tanaka, H., Winter, M. A., Perkison, W. B., Brown, E. L., Aguilar, D. A., & Hanis, C. L. (2022) · Chronic Illness · doi:10.1177/17423953221089315 · Cited by 6
Fitzpatrick, S. L., Mayhew, M., Catlin, C., Firemark, A. J., Gruß, I., Nyongesa, D. B., O'Keeffe-Rosetti, M. C., Rawlings, A. M., Smith, D. H., Smith, N. X., et al. (2022) · The Permanente Journal · doi:10.7812/tpp/21.056 · Cited by 6
The Global Burden of Disease: A Focus on Type II Diabetes
Forray, A. I., Gavrilaș, L., Craciun, A. E., & Borzan, C. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-32047-7_68-1 · Cited by 11
Long-term cost-effectiveness of health behaviour intervention to manage type 2 diabetes in Nepal
Dahal, P. K., Vandelanotte, C., Rawal, L. B., Mahumud, R. A., Paudel, G., Lloyd, M., Baek, Y., Karmacharya, B. M., Sugishita, T., & Ademi, Z. (2025) · BMC Medicine · doi:10.1186/s12916-025-03981-8 · Cited by 5
“Furthermore, systematic reviews of health behaviour interventions in high-income countries indicated that interventions intended to prevent T2DM are cost-effective or cost-saving in the longer term [11–13].”
Population-Level Approaches to Preventing Type 2 Diabetes Globally
Siegel, K. R., & Albright, A. L. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.010 · Cited by 6
Self-citationBasu, A., Hooyman, A., Richardson, L. A., Alman, A. C., & Snell‐Bergeon, J. K. (2023) · Nutrients · doi:10.3390/nu15214620 · Cited by 6
“Lifestyle interventions including dietary modifications have been shown to reverse/slow the progression of prediabetes to diabetes [41–43]; our findings provide evidence on this association in the context of dietary fiber.”
BackgroundShakya, P., Shrestha, A., Bajracharya, M., Shrestha, A., Kulseng, B. E., Karmacharya, B. M., Shrestha, S., Das, S., Shrestha, I. B., Barun, K., et al. (2023) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2023-000702 · Cited by 5
Graue, M., Igland, J., Oftedal, B. F., Haugstvedt, A., Riise, H. K. R., Zoffmann, V., Jenum, A. K., Richards, D. A., & Kolltveit, B. H. (2024) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2024.2337071 · Cited by 5
Pagano, R., Ostolin, T. L. V. D. P., Fonseca, D. C., Marcadenti, A., Carvalho, A. P. P. F., Weber, B., Daltro, C., Lara, E. M. D. S., Nolêto, F. C. M., Bressan, J., et al. (2025) · Nutrients · doi:10.3390/nu17152518 · Cited by 5
Maruthur, N. M., Chan, S., Arnold, E. A., Brown, M., NASS, C. M., Tseng, E., Berkowitz, S. A., Wang, N., Yeh, H., Han, D., et al. (2025) · Clinical Diabetes · doi:10.2337/cd25-0043 · Cited by 4
A Data-Driven Approach for Estimating Type 2 Diabetes-Related Costs in Greece
Nika, E., Tsiampalis, T., Sachlas, A., Liberopoulos, E. N., Bersimis, S., & Géorgakèllos, D. A. (2025) · Journal of Market Access & Health Policy · doi:10.3390/jmahp13040053 · Cited by 5
“Public health interventions with costs less than USD 50,000 per QALY are broadly recognized as exhibiting strong value and being deemed cost-effective [61,62].”
Xiong, Y., Huo, Z., Wong, S. Y. S., & Yip, B. H. K. (2023) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.89 · Cited by 6
Deenik, J., van Lieshout, C., Driel, H. F. V., Frederix, G., Hendriksen, I. J. M., van Harten, P. N., & Tenback, D. E. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac022 · Cited by 6
Zheng, M., Soumya, S., Begum, M., Bernardo, C., Stocks, N. P., Jahan, H., & González‐Chica, D. A. (2023) · Diabetic Medicine · doi:10.1111/dme.15170 · Cited by 6
AbdulKareem, N. G., Jassim, N. A., Mohammed, Z., & Alkabban, M. (2024) · Journal of Bioscience and Applied Research/Journal of Bioscience and Applied Research · doi:10.21608/jbaar.2024.361942 · Cited by 4
Ackermann, R. T. (2025) · Diabetes Care · doi:10.2337/dci24-0100 · Cited by 5
Ng, B. P., Cheng, Y. J., Rutledge, S., Cannon, M. J., Zhang, P., & Smith, B. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241757 · Cited by 4
“However, more research is needed to better understand the effectiveness and cost-effectiveness of virtual/on-line programs [20].”
BackgroundSelf-citationQuality of Diabetes Care in the USA
Alencherry, B., & Bruemmer, D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01503-5 · Cited by 4
Kranz, R., Kettler, C., Koeder, C., Husain, S., Anand, C., Schoch, N., & Englert, H. S. (2023) · Nutrients · doi:10.3390/nu15245045 · Cited by 3
“Similarly, several studies of type 2 diabetes prevention for high-risk individuals have been shown to be cost effective or cost saving [20,24].”
BackgroundPowter, H., Lambert, K., & Nicholls, N. (2024) · Health Promotion Journal of Australia · doi:10.1002/hpja.841 · Cited by 3
Is Prediabetes Overdiagnosed? Yes: A Patient-Epidemiologist’s Experience
Marx, R. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3093 · Cited by 3
“29 Population-wide interventions demonstrate an effect on body mass index (BMI) but not on prevalence of overweight, obesity, and diabetes.”
BackgroundHenson-García, M., Malthaner, L., Jetelina, K. K., Mackert, M., Allicock, M. A., & McKay, S. (2024) · Psychological Reports · doi:10.1177/00332941241256880 · Cited by 3
Golubić, R., Car, J., & Nicolaides, K. H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16070 · Cited by 3
“27 While strategies to prevent T2D targeting at-risk groups and whole populations have been cost-effective or cost-saving, 28”
Statins for primary prevention of cardiovascular disease in Germany: benefits and costs
Dressel, A., Fath, F., Krämer, B. K., Klose, G., & März, W. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02608-5 · Cited by 4
“The cost of preventing diabetes mellitus through intensive lifestyle modification is likely to be between USD 6000 and USD 13,000 per QALY [36–38], but has also been reported in the order of USD 50,000 per QALY [39].”
Sathish, T., Shaw, J. E., Oldenburg, B. F., & Mahal, A. S. (2020) · Diabetes Care · doi:10.2337/dc20-2124 · Cited by 3
“(1) published a systematic review of studies on the costeffectiveness of interventions for the prevention of type 2 diabetes.”
BackgroundPredicting Sensitivity to Adverse Lifestyle Risk Factors for Cardiometabolic Morbidity and Mortality
Pomares‐Millan, H., Poveda, A., Atabaki‐Pasdar, N., Johansson, I., Björk, J., Ohlsson, M., Giordano, G. N., & Franks, P. W. (2022) · Nutrients · doi:10.3390/nu14153171 · Cited by 3
“Moreover, once manifest, T2D and CVD often cause life-threatening health complications that are often difficult and costly to treat [2].”
Background
Metadata
- Authors
- Zhou, X., Siegel, K. R., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Albright, A. L., & Zhang, P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University of Central Florida (US)
- Oak Ridge Institute for Science and Education (US)
- Corresponding author
- Zhang, Ping
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-06-11
- Volume
- 43
- Issue
- 7
- Pages
- 1593-1616
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3035894501
- Semantic Scholar
- d3d0aa492aa63ebbd3b3bb0388faca0d497a3190
- Cited by
- 173
- References
- 67
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 43 · 2023: 33 · 2022: 24 · 2021: 20 · 2020: 6
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes prevention, cost-effectiveness, high-risk individuals, population-based prevention, lifestyle intervention, metformin, Diabetes Prevention Program, sugar-sweetened beverage tax, fruit and vegetable subsidies, community-based education, lay health workers, incremental cost-effectiveness ratio
- MeSH terms
- Adult, Aged, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Endocrinology, Health Expenditures, Health Promotion, Humans, Life Style, Metformin, Middle Aged, Patient Education as Topic, Population Surveillance, Prediabetic State, Preventive Medicine, Risk Factors, Health Care Costs, Quality-Adjusted Life Years, Community Networks, Risk Reduction Behavior, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.